Back to top

BeyondSpring presents interim phase 2 data on 303 study

BeyondSpring (BYSI) announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer, NSCLC, after di...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeyondSpring Inc. (BYSI)